Key result
Macrophages play a crucial role in myocardial inflammation and fibrosis, making the regulation of their phenotypic transformation a potential therapeutic target for cardiomyopathy.
Why the study?
Although experimental evidence shows macrophage-targeted therapy is promising in cardiomyopathy, clinical translation remains challenging.
Regulating the phenotypic transformation of macrophages from pro-inflammatory (M1) to anti-inflammatory/reparative (M2) states offers a promising therapeutic strategy for treating various forms of cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Macrophage modulation should not yet change cardiomyopathy care; leaves open need for interventional trials to test phenotypic targeting.
Cardiomyopathy is a major cause of heart failure, leading to systolic and diastolic dysfunction and promoting adverse cardiac remodeling. Macrophages, as key immune cells of the heart, play a crucial role in inflammation and fibrosis. Moreover, exogenous and cardiac resident macrophages are functionally and phenotypically different during cardiac injury. Although experimental evidence has shown that macrophage-targeted therapy is promising in cardiomyopathy, clinical translation remains challenging. In this article, the molecular mechanism of macrophages in cardiomyopathy has been discussed in detail based on existing literature. The issues and considerations of clinical treatment strategies for myocardial fibrosis has also been analyzed.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2022) conducted a review in Cardiomyopathy. Macrophage-targeted therapy was evaluated. Macrophages play a crucial role in myocardial inflammation and fibrosis, making the regulation of their phenotypic transformation a potential therapeutic target for cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: